RT Journal Article SR Electronic T1 Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer JF Cancer Biology and Medicine JO Cancer Biol Med FD China Anti-Cancer Association SP 212 OP 227 DO 10.20892/j.issn.2095-3941.2017.0054 VO 14 IS 3 A1 Zhang, Meng A1 Liu, Ergang A1 Cui, Yanna A1 Huang, Yongzhuo YR 2017 UL http://www.cancerbiomed.org/content/14/3/212.abstract AB Multidrug resistance (MDR) is a major obstacle to successful cancer treatment and is crucial to cancer metastasis and relapse. Combination therapy is an effective strategy for overcoming MDR. However, the different pharmacokinetic (PK) profiles of combined drugs often undermine the combination effect in vivo, especially when greatly different physicochemical properties (e.g., those of macromolecules and small drugs) combine. To address this issue, nanotechnology-based codelivery techniques have been actively explored. They possess great advantages for tumor targeting, controlled drug release, and identical drug PK profiles. Thus, a powerful tool for combination therapy is provided, and the translation from in vitro to in vivo is facilitated. In this review, we present a summary of various combination strategies for overcoming MDR and the nanotechnology-based combination therapy.